Global CRO footprint Cromos Pharma operates as an international CRO with offices in the US and Europe and regional strength in US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye. This breadth enables rapid patient recruitment and multi-region study execution, presenting opportunities to pursue global trials and any sponsor seeking diverse regulatory landscapes.

MD‑led expertise With a team where 95 percent are MDs and capabilities spanning study design, medical writing, regulatory affairs, site management, patient recruitment, and data management, Cromos offers high-quality, clinically-driven services that can be positioned to sponsors prioritizing scientific rigor and regulatory readiness.

Enrollment efficiency The company emphasizes accelerated study start-up timelines and has achieved enrollment timelines met or reduced in 95 percent of trials, signaling strong performance in patient recruitment and trial initiation—a compelling selling point for sponsors facing aggressive timelines.

Recent growth highlights New Lisbon office in 2024 and active participation in high-profile collaborations (e.g., MAIA Biotechnology partnership) indicate ongoing expansion and industry validation, suggesting opportunities to engage sponsors seeking CROs with growing capacity and strategic partnerships.

Industry positioning Cromos operates in a competitive CRO landscape with mid-sized scale (employees 51-200) and revenue indicators in the lower to mid billions range, offering a value proposition of personalized service with global reach—ideal for mid-market and niche biotech/pharma sponsors seeking attentive execution and regulatory credibility.